Ovalicin 是一种靶向 MetAP2、HRH2、JAK2 和 TRPV1 的多靶点抑制剂,具有抗炎和抗特应性皮炎活性,它通过与 MetAP2 共价结合抑制其功能,从而阻断肠脑炎微孢子虫和角膜维塔 forma 虫的复制,在感染小鼠模型中减轻肠道损伤并延长生存期,且未显示出明显的肝肾毒性,同时能够减弱 LPS 诱导的钙内流,减少皮肤中巨噬细胞和肥大细胞的浸润,并调控 IL-31 等炎症相关基因的表达,有效缓解小鼠模型的过敏症状,可用于微孢子虫病和特应性皮炎的研究。
产品编号: MS-Z50526 CAS No.: 19683-98-8 分子式: C16H24O5 分子量: 296.36
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

Ovalicin 是一种靶向 MetAP2、HRH2、JAK2 和 TRPV1 的多靶点抑制剂,具有抗炎和抗特应性皮炎活性,它通过与 MetAP2 共价结合抑制其功能,从而阻断肠脑炎微孢子虫和角膜维塔 forma 虫的复制,在感染小鼠模型中减轻肠道损伤并延长生存期,且未显示出明显的肝肾毒性,同时能够减弱 LPS 诱导的钙内流,减少皮肤中巨噬细胞和肥大细胞的浸润,并调控 IL-31 等炎症相关基因的表达,有效缓解小鼠模型的过敏症状,可用于微孢子虫病和特应性皮炎的研究。

生物实验数据

生物活性 Ovalicin is a multi-target inhibitor targeting MetAP2, HRH2, JAK2, and TRPV1 with anti-inflammatory and anti-atopic dermatitis activities; it inhibits MetAP2 function by covalently binding to it, thereby blocking the replication of Enterocytozoon bieneusi and Vittaforma corneae, reduces intestinal damage and prolongs survival in infected mouse models without showing obvious hepatorenal toxicity, and attenuates LPS-induced calcium influx, decreases macrophage and mast cell infiltration in the skin, and modulates the expression of inflammation-related genes such as IL-31, effectively alleviating allergic symptoms in mouse models, making it useful for research on microsporidiosis and atopic dermatitis.
IC50 & Target

JAK2

 

MetAp2

 

TRPV1

 

体外研究
(In Vitro)

Ovalicin (10 μM; 10 d) 可在 RK-13 兔肾细胞中以无毒性浓度处理 10 天后,使肠脑炎微孢子虫 (IC50=0.004 μM) 和角膜维塔 forma 虫 (IC50=0.002 μM) 的复制抑制率超过 70%。
Ovalicin (1-200 μg/mL; 24-72 h) 可呈剂量依赖性降低 DH82 细胞活力。
Ovalicin (2-8 μg/mL; 1 d) 可剂量依赖性地降低经 LPS 预处理的 DH82 细胞升高的细胞活力。
Ovalicin (2-10 μg/mL; 1 d) 可剂量依赖性地抑制 DH82 细胞中 LPS 诱导的 IL4、IFNG、TRPV1、HRH2 和 IL31RA mRNA 表达上调,其中 10 μg/mL Ovalicin 的抑制作用强于 Dexamethasone (MS-E10819)。
Ovalicin (2-10 μg/mL; 1 d) 可通过降低 IL31RA、OSMR、JAK2 和 p-STAT3 的表达,剂量依赖性地抑制 DH82 细胞中 LPS 诱导的 IL-31 信号通路激活;在 4 和 10 μg/mL 浓度下,其抑制作用强于 Dexamethasone (MS-E10819)。
Ovalicin (10 μg/mL; 1 d) 可减弱 LPS 诱导的 DH82 细胞内钙内流,其作用效果强于 Dexamethasone (MS-E10819) 和 Ruxolitinib (MS-D98105)。
Ovalicin (2-10 μg/mL; 1 d) 可通过降低 iNOS、COX2、NF-κB 和 ROS 水平,以剂量依赖的方式抑制 DH82 细胞中 LPS 诱导的炎症反应,且其抑制效果强于 Dexamethasone (MS-E10819)。

Cell Viability Assay

Cell Line: canine macrophage cell line DH82
Concentration: 1-200 μg/mL
Incubation Time: 24 h; 48 h; 72 h
Result: Decreased DH82 cell viability dose-dependently.
Maintained more than 90% cell survival at 1 and 10 μg/mL after 24 and 48 hours.

Cell Viability Assay

Cell Line: LPS-pretreated canine macrophage cell line DH82
Concentration: 2-8 μg/mL
Incubation Time: 1 day
Result: Decreased cell viability dose-dependently in LPS-pretreated DH82 cells, where LPS pretreatment had increased cell viability compared to LPS-untreated cells.

Real Time qPCR

Cell Line: LPS-pretreated canine macrophage cell line DH82
Concentration: 2-10 μg/mL
Incubation Time: 1 day
Result: Significantly attenuated LPS-induced upregulation of IL4 and IFNG mRNA expression.
Exerted a stronger inhibitory effect on these mRNA levels at 10 μg/mL than Dexamethasone.\nSignificantly inhibited LPS-induced increases in TRPV1 and HRH2 mRNA expression.
Exerted a stronger inhibitory effect than dexamethasone and ruxolitinib.
More significantly inhibited LPS-induced increases in IL31RA, TRPV1, and HRH2 mRNA expression than ruxolitinib.

ELISA Assay

Cell Line: LPS-pretreated canine macrophage cell line DH82
Concentration: 2-10 μg/mL
Incubation Time: 1 day
Result: Significantly inhibited LPS-induced IL-31 protein expression in DH82 cells.
Exerted a stronger inhibitory effect than dexamethasone treatment.
体内研究
(In Vivo)

Ovalicin (5-20 mg/kg;皮下注射;每日) 以 5 mg/kg 剂量每日皮下注射给药时,可统计学显著延长 V. corneae 感染的无胸腺小鼠的生存期,并减轻寄生虫相关的小肠损伤。
Ovalicin (1-10 μg/mL;局部给药;每日 1 次;连续 5 天) 可通过减少真皮免疫细胞浸润、恢复血清指标正常水平、抑制 IL-31 信号通路及瘙痒相关 gene 表达,呈剂量依赖性缓解 DNCB 诱导的 BALB/C 小鼠特应性皮炎症状。
Ovalicin (10 μg/mL;局部给药;每日 1 次;连续 5 天) 不会在健康 BALB/C 小鼠中诱导皮肤形态改变或皮炎。

Animal Model: CRL:CD-1nuBR (7-week-old male, intraperitoneally inoculated with Vittaforma corneae spores)
Dosage: 5 mg/kg; 10 mg/kg; 20 mg/kg
Administration: s.c.; daily
Result: Prolonged mean survival time to 19.9 days and reduced mean number of parasite-associated small intestinal lesions to 11.6 at 5 mg/kg.
Showed no statistically significant increases in survival time relative to controls at 10 mg/kg or 20 mg/kg.
Showed no significant differences in mean numbers of lesions in the small intestine, liver, and pancreas relative to controls at 10 mg/kg or 20 mg/kg.
Resulted in full study duration survival with no drug-associated lesions in uninfected mice at 20 mg/kg.
Animal Model: BALB/C (female, 5 weeks old, atopic dermatitis induced by DNCB)
Dosage: 1 μg/mL; 10 μg/mL
Administration: topical; daily; 5 days
Result: Decreased the number of IBA1-positive macrophages and mast cells infiltrated in the dermis in a dose-dependent manner.
Significantly reduced dermatitis lesion scores (assessed by hemorrhage, scarring, edema, and erosion).
Reversed elevated serum albumin and total protein levels.
Decreased elevated serum IL-31 concentration in a dose-dependent manner.
Reduced mRNA expression of TRPV1 and HRH2 in skin tissue.
Decreased expression of IL-31 receptor (IL-31R) in skin tissue.
Enhanced re-epithelialization and granulation tissue formation in skin.

化学信息

分子量 296.36
分子式 C16H24O5
CAS No. 19683-98-8

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础